Inhibitory effect of captopril on cell degeneration and growth.
Makoto Nagano
Abstract
Makoto Nagano
Abstract
Since the first administration of the angiotensin-converting enzyme (ACE) inhibitor captopril for the treatment of essential hypertension, it has been recognized that the ACE inhibitor has a positive influence on the cardiovascular system, on both a molecular and a clinical level.Over the past 25 years, the indications for ACE inhibitors have spread into many fields. During this period, interesting effects of ACE inhibitors in noncardiac fields have been reported. The present review outlines two studies regarding the protective effect of captopril on cardiomyopathy and its therapeutic effect on sarcoidosis.
OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Since the first administration of the angiotensin-converting enzyme (ACE) inhibitor captopril for the treatment of essential hypertension, it has been recognized that the ACE inhibitor has a positive influence on the cardiovascular system, on both a molecular and a clinical level.Over the past 25 years, the indications for ACE inhibitors have spread into many fields. During this period, interesting effects of ACE inhibitors in noncardiac fields have been reported. The present review outlines two studies regarding the protective effect of captopril on cardiomyopathy and its therapeutic effect on sarcoidosis.
Key concepts: Captopril, Medicine, Angiotensin-converting enzyme, ACE inhibitor, Enzyme inhibitor, Pharmacology, Internal medicine, Cardiomyopathy